Pharmaceutical major Diosynth supports COVID-19 vaccine manufacture in the US - Reports Watch

FUJIFILM Diosynth Biotechnologies, a globally leading CDMO (contract development and manufacturing organization) for biologics, gene therapies, and viral vaccines, has come up with a major announcement that its Flexible Biomanufacturing Facility (FBF) located at College Station, Texas, will be lending significant support to the manufacture of a potential COVID-19 vaccine candidate. The pharmaceutical giant’s latest move comes in the wake of an ongoing U.S. government program, dubbed as Operation Warp Speed, which aims to ensure that the entire American population receives doses of the safest and most effective COVID-19 vaccine, at the earliest.

It has been reported that the Biomedical Advanced Research and Development Authority (BARDA) had recently issued a task order through the Texas A&M University System (TAMUS) and the Center for Innovation in Advanced Development & Manufacturing (CIADM). Reportedly, the task order reserves the FBF’s manufacturing capacity till the end of 2021. It is further helping Diosynth expand the vaccine production with capacity expansion investments. The FBF, for the record, is one of three production facilities at the Texas campus of FUJIFILM Diosynth Biotechnologies. Dr. Gerry Farrell, the Chief Operating Officer (COO) at Diosynth, detailed on the matter, “Our leading scientists and engineers in College Station are honored to support COVID-19 vaccine manufacturing with the goal of delivering a safe and effective vaccine to the U.S. population. We will allocate the reserved capacity based on direction provided by the U.S. government, and similar to our North Carolina site, we expect a portion of the reserved capacity to be allocated to Novavax, Inc. for its NVX-CoV2373 COVID-19 vaccine candidate.”

On July 23, Diosynth had announced an agreement with Novavax, Inc. that was intended for the bulk production of the NVX-CoV2373 vaccine candidate at its North Carolina site. The technology transfer will take place from the North Carolina site to Texas facility during late 2020, while the vaccine’s expanded mass production is expected to begin in early 2021.

Let's block ads! (Why?)